Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Operating Cash Flow

Cash generated by the company's core business operations during the period.

Shattuck Labs, Inc.NASDAQ: STTK

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $13.42M (cash outflow) rose 11.6% year over year, ahead of the -26.8% change in trailing-twelve-month operating cash flow. Sequentially, it rose 58.1% from the prior quarter. Over 3 fiscal years it compounded at -25.0% a year.

Context

  • Operating cash flow amounted to 3988.2% of revenue in FY2025, up 2930.4 pp from a year earlier.
  • Operating cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of -26.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.42M+58.1% QoQ
Last fiscal yearDec 2025
-$39.88M-34.1% YoY
LTMMar 2026
-$41.27M-26.8% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.6%——
1 year-34.1%——
3-year CAGR-25.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(39.88M) USD
Year-over-year change
+34.1%

Operating Cash Flow vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.8% is the 6th highest of 9, against a peer median of +8.9%.
  • Operating cash flow amounts to 4127.4% of revenue for STTK, versus a peer median of 50.1%.
STTK Competitors
Operating Cash Flow for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$4.39B USD+12765.8%+925.8%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$189.95M USD-41.2%+1.1%50.1%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$75.36M USD-4529.6%+15.5%634.2%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$53.61M USD+71.4%—23.6%
STTKShattuck Labs, Inc.LTM Mar 2026$41.27M USD-26.8%-25.0%4127.4%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$34.03M USD-376.5%——
FTHFaeth Therapeutics, Inc.LTM Jun 2026$33.86M USD+39.5%-19.4%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$27.3M USD-10.9%+6.0%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$17.27M USD+28.6%+4.3%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥13.15M CNY—-73.5%—
Peer median (excluding STTK) —+8.9%+4.3%50.1%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
Deferred Income Tax3.04M0000
Stock-Based Compensation5.47M6.46M6.94M9.55M7M
Change in Working Capital(23.55M)(4.46M)(4.1M)3.02M(785K)
Accounts Receivables00000
Inventory00000
Accounts Payables7.87M(2.84M)(5.63M)832K(318K)
Other Working Capital(31.41M)(1.62M)1.53M2.19M(467K)
Other Non-Cash Items1.52M2.38M(816K)(1.5M)(971K)
Operating Cash Flow(57.12M)(94.5M)(81.23M)(60.52M)(39.88M)
Capital Expenditures(7.93M)(11.61M)(407K)(59K)(71K)
Acquisitions (Net)2.52M104K000
Purchases of Investments(204.09M)(132.38M)(79.73M)(93.55M)(43.42M)
Sales of Investments201.58M193.33M191M85.1M35.6M
Other Investing Activities(2.52M)0000
Investing Cash Flow(10.44M)49.44M110.86M(8.51M)(7.89M)
Debt Repayment00000
Common Stock Issued1.93M171K48.67M(17K)44.48M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(53K)804K(65K)
Financing Cash Flow1.93M171K48.62M787K44.57M
Effect of Forex Changes00000
Net Change in Cash(65.63M)(44.89M)78.25M(68.24M)(3.2M)
Free Cash Flow(65.04M)(106.11M)(81.64M)(60.57M)(39.95M)

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.